Galectin-3

Bioxytran Names Leslie Ajayi as Interim CMO and Head of the Medical Advisory Board

Retrieved on: 
Monday, July 31, 2023
Clinical Science (journal), Disulfiram-like drug, GSK plc, Insulin resistance, OAU, Pregnancy, University, PD, Internal medicine, Pharmacovigilance, Roche, Big Pharma, COVID-19, Baylor University, Clinical trial, Pharmacokinetics, ACEI, Viral, Medicine, CMO, Doctor of Philosophy, Perindopril, Literature, Galectin-3, MD, Cilazapril, Saint James School of Medicine, Amlodipine, Merck, Type, Ross University, Pharmacology, Safety, Obafemi Awolowo University, Academic and Research Center (Ohio University), Conditional sentence, Pharmaceutical industry, Outline of health sciences, Pfizer

He will report to the CEO Dr David Platt and chair the Medical Advisory Board.

Key Points: 
  • He will report to the CEO Dr David Platt and chair the Medical Advisory Board.
  • He is a fully trained physician leader with international specialty training in internal medicine, cardiovascular medicine, and clinical pharmacology.
  • Bioxytran has one of the most ambitious pipeline buildouts I have every seen,” said Dr. Leslie Ajayi.
  • I also look forward to building out the medical advisory board.”

Global Galectin Inhibitors Market Report 2023: Featuring BioXyTran, Galectin Therapeutics, HiFiBiO, PureTech Health & More - ResearchAndMarkets.com

Retrieved on: 
Monday, April 24, 2023
Health, Pharmaceutical, Infection, Fatty liver disease, Esophageal varices, Biotechnology, NASH, Myocardial infarction, COVID-19, Indication, Pathology, Cancer, Galectin-3, Head, Cirrhosis, Mpox, Medicine, Research, Attention, Lung cancer, Pulmonary fibrosis, US, Protein, Galectin, Patient, Viral, Knowledge, FDA, Pembrolizumab, Therapy, IND, Family, Safety, Disease, Pharmaceutical industry, Dietary supplement

The "Global Galectin Inhibitors Market Trends & Clinical Trials Insight 2023" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Galectin Inhibitors Market Trends & Clinical Trials Insight 2023" report has been added to ResearchAndMarkets.com's offering.
  • The member of the galectin family that has drawn the most attention and developed into the best understood is galectin-3.
  • The most well-known and likely to succeed of the candidates created to date is GR-MD-O2, the lead candidate of Galectin Therapeutics.
  • As companies performing preclinical and clinical investigations release their findings, the market is predicted to grow in the coming years.

Galecto to Present Two Posters at AACR Annual Meeting 2023

Retrieved on: 
Thursday, April 13, 2023
Pancreatic cancer, AACR, Neoplasm, Cancer, Adenocarcinoma, NSCLC, Lung cancer, Fibrosis, Galectin-3, American Association for Cancer Research, Biology, Tumor microenvironment, Pharmaceutical industry, Galecto Biotech

BOSTON, April 13, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and world leader in galectin biology focused on the development of novel treatments for fibrosis and cancer, today announced it will present two posters at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2023, taking place April 14-19 in Orlando, Florida.

Key Points: 
  • BOSTON, April 13, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and world leader in galectin biology focused on the development of novel treatments for fibrosis and cancer, today announced it will present two posters at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2023, taking place April 14-19 in Orlando, Florida.
  • Galecto is currently conducting a Phase 2a trial of GB1211, a small molecule galectin-3 inhibitor, in combination with atezolizumab for the first-line treatment of non-small cell lung cancer (NSCLC).
  • Many tumors overexpress galectin-3, which is linked to several cancer promoting mechanisms, including those linked to checkpoint inhibitor and chemotherapy resistance, and may ultimately lead to worse clinical outcomes.
  • Several other forms of galectins, such as galectin-1, are also associated with cancer.

Nature Reviews Drug Discovery Article Offers Independent Support for ProLectin-I in Fibrosis and ProLectin-M as an Antiviral Drug

Retrieved on: 
Wednesday, February 22, 2023
Polysaccharide, Malignancy, Viral, Cancer, Drug discovery, Article, Fibrosis, Drug development, Journal, Idiopathic pulmonary fibrosis, NASH, IPF, Drug design, COVID-19, OTCQB, Pharmaceutical industry, Medical device, Galectin-3

The article published on 9 February, 2023, was titled “Targeting galectin-driven regulatory circuits in cancer and fibrosis“ was authored by Karina Marino, Alejandro Cagnoni, Diego Croci, and Gabriel Rabinovich.

Key Points: 
  • The article published on 9 February, 2023, was titled “Targeting galectin-driven regulatory circuits in cancer and fibrosis“ was authored by Karina Marino, Alejandro Cagnoni, Diego Croci, and Gabriel Rabinovich.
  • The review article independently supports Bioxytran’s drug development program for fibrosis and antiviral disease treatment.
  • The theoretical basis of the drug design was inhibition of multiple galectins like those highlighted in the journal article.
  • Bioxtyran developed multiple galectin antagonists and the review article independently bolstered the scientific basis of its drug development.

Bioxytran Establishes Indian Subsidiary in Preparation of Commercialization

Retrieved on: 
Wednesday, December 14, 2022
CDSCO, Pulmonary fibrosis, FDA, Degenerative disease, Stroke, Galectin-3, Central Drugs Standard Control Organisation, OTCQB, Virology, Hypoxia, COVID-19, Pharmaceutical industry

BOSTON, MASSACHUSETTS, Dec. 14, 2022 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat COVID-19 and other viral causing diseases announced that it has established an Indian subsidiary (Pharmalectin India Private Limited).

Key Points: 
  • BOSTON, MASSACHUSETTS, Dec. 14, 2022 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat COVID-19 and other viral causing diseases announced that it has established an Indian subsidiary (Pharmalectin India Private Limited).
  • The purpose of the subsidiary is to launch commercial product sales of ProLectin-M should the company receive Central Drugs Standard Control Organization (CDSCO) approval.
  • The Indian manufacturing plant is an FDA approved facility capable of supporting the Indian market with a population of 1.4 billion people.
  • Bioxytran, Inc. is a clinical stage biotechnology company developing novel therapies targeting the treatment of significant unmet medical needs in virology, degenerative disease, and hypoxia.

Bioxytran Interview at the Emerging Growth Conference

Retrieved on: 
Monday, December 12, 2022
Conference, Pulmonary fibrosis, Investment, Clinical trial, Degenerative disease, Growth, Stroke, Galectin-3, OTCQB, Virology, Hypoxia, COVID-19, Pharmaceutical industry, Broadcasting

Investors are encouraged to preregister to ensure you are able to attend the conference and receive any updates that are released.

Key Points: 
  • Investors are encouraged to preregister to ensure you are able to attend the conference and receive any updates that are released.
  • The Emerging Growth conference is an effective way for public companies to present and communicate their new products, services and other major announcements to the investment community from the convenience of their office, in a time efficient manner.
  • The Conference focus and coverage includes companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long term growth.
  • Bioxytran, Inc. is a clinical stage biotechnology company developing novel therapies targeting the treatment of significant unmet medical needs in virology, degenerative disease, and hypoxia.

Bioxytran, Inc. Announces the Reinitiation of Coverage of Its Stock by Avise Analytics

Retrieved on: 
Tuesday, November 22, 2022
WACC, Hypoxia, Stroke, OTC, COVID-19, Virology, Safety, Patient, Research report, DCF, Degenerative disease, Vaccine, Research, Therapy, Pulmonary fibrosis, OTCQB, Clinical trial, Galectin-3, FDA, Pharmaceutical industry

ProLectin-M may have significant safety, efficacy, and dosing advantages over currently marketed therapies in its class.

Key Points: 
  • ProLectin-M may have significant safety, efficacy, and dosing advantages over currently marketed therapies in its class.
  • The targeted virus types represent an addressable market of over 10 million patients and a multi-billion-dollar market.
  • Positive results from the upcoming Phase III trial of ProLectin-M could position the drug to capture significant market share.
  • However, the inability to garner sufficient funds for the drug development process may delay the clinical process of both Prolectin-M and BXT-25.

Bioxytran Scientific Advisor Releases New Book on Brain Metabolism

Retrieved on: 
Tuesday, October 25, 2022
Galectin-3, Viewer, Metabolic Score for Insulin Resistance, Tissue, Hardcover, GLOBE, Hypoxia, ISBN, Cortex, CSD, Depression, Oxygen, Ebook, COVID-19, Technology, Clinical trial, FDA, TMS, BMS, Brain, Research, Cortical spreading depression, Pulmonary fibrosis, Drug development, MDX, Virology, Degenerative disease, Stroke, Springer, Wrist, Medical imaging, Pharmaceutical industry

BOSTON, MASSACHUSETTS, Oct. 25, 2022 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (BIXT), (the “Company”), a clinical stage biotechnology company developing oral drugs to treat COVID-19 and other viral causing diseases announced that Bioxtran’s Scientific Advisor Prof. Avraham Mayevsky’s book titled Cortical Spreading Depression of Leão: From Mitochondrial Function to Brain Metabolic Score (BMS) (ISBN: 978-3-031-08068-5) was published this month, by the well-known publishing house, Springer. It is available by eBook or Hardcover. The book is directly tied to Bioxytran’s Hypoxia platform technology which uses Oxysense; an analytical method that utilizes the MDX Viewer, which is an FDA approved device to measure tissue oxygenation. Oxysense measures the consumption of oxygen in tissues on a cellular level. Oxysense produces the Brain Metabolic Score (“BMS”), which is a vital part of the approval process for Bioxytran’s acellular oxygen carrier (“AOC”) molecule called BXT-25. Bioxytran has the exclusive license to use the MDX Viewer in clinical research, and plans on using the BMS in its clinical trials for ischemic stroke.

Key Points: 
  • The book contains all aspects of brain energy metabolism and other physiological functions related to Cortical Spreading Depression which is the essence of how the brain consumes oxygen.
  • Oxysense produces the Brain Metabolic Score (BMS), which is a vital part of the approval process for Bioxytrans acellular oxygen carrier (AOC) molecule called BXT-25.
  • The book expands on the concept of Cortical Spreading Depression (CSD) in brain animal models.
  • Having the ability to measure tissue oxygenation in real-time opens up a whole new paradigm in drug development said Bioxytrans Scientific Advisor, Prof. Avraham Mayevsky.

Galectin Therapeutics Discusses Corporate Transformation, Progress of NAVIGATE Trial and Outlines Strategy for Potential Phase 2 Cancer Immunotherapy Trial at Annual Meeting

Retrieved on: 
Monday, December 13, 2021
Therapy, Galectin, USAN, Fatty liver disease, Board, Clinical trial, Cirrhosis, Population, Animal, NASDAQ, Chemistry, Liver, University of Chicago Medical Center, Argaw Bedaso, Heart, Cancer, Annual general meeting, FDA, Safety, Physician, Galectin-3, Esophageal varices, Johns Hopkins, Immunotherapy, Lung, Head, Drug development, GLOBE, Annual, Hope, Board of directors, Annual Meetings of the International Monetary Fund and the World Bank Group, Liver disease, COVID-19, SEC, GALT, Marketing, Coronavirus, Chronic liver disease, Consultant, Food, Company, Efficacy, Private Securities Litigation Reform Act, NASH, Kidney, International Studies of Infarct Survival, Rosenberg, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Patient, Leadership, University, DRS, Fibrosis, Pharmaceutical industry, Medical device

NORCROSS, Ga., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectins, provided an update on its strategy and clinical trial progress at its 2021 Annual Meeting, held virtually on December 3, and reported that shareholders approved all proposals, including the reelection of its Board of Directors.

Key Points: 
  • Compared to a year ago, Galectin Therapeutics has been transformed into a new company, said Joel Lewis, Chief Executive Officer and President of Galectin Therapeutics.
  • Despite the challenges presented by COVID-19, particularly outside the U.S., the NAVIGATE Phase 2b/3 trial in NASH cirrhosis has been initiated in all countries originally selected for participation.
  • Galectin Therapeutics is dedicated to developing novel therapies to improve the lives of patients with chronic liver disease and cancer.
  • Galectin Therapeutics and its associated logo is a registered trademark of Galectin Therapeutics Inc. Belapectin is the USAN assigned name for Galectin Therapeutics galectin-3 inhibitor GR-MD-02.

Galectin Therapeutics Announces Positive Top-Line Results from a Phase 1b Clinical Trial Extension of Belapectin in Combination with KEYTRUDA® in Advanced Metastatic Melanoma and Head and Neck Cancer

Retrieved on: 
Friday, July 9, 2021
Proteins, Branches of biology, Lectins, Cancer treatments, Galectin-3, Galectin, MTOR, Cancer, Pembrolizumab

Galectin-3 also has a significant role in cancer, and the Company is supporting a Phase 1 study in combined immunotherapy of belapectin and KEYTRUDA in treatment of advanced melanoma and in head and neck cancer.

Key Points: 
  • Galectin-3 also has a significant role in cancer, and the Company is supporting a Phase 1 study in combined immunotherapy of belapectin and KEYTRUDA in treatment of advanced melanoma and in head and neck cancer.
  • Galectin Therapeutics is dedicated to developing novel therapies to improve the lives of patients with chronic liver disease and cancer.
  • Although subsequent events may cause its views to change, management disclaims any obligation to update forward-looking statements.
  • Galectin Therapeutics and its associated logo is a registered trademark of Galectin Therapeutics Inc. Belapectin is the USAN assigned name for Galectin Therapeutics galectin-3 inhibitor GR-MD-02.